Drugs / SRSD107
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07655427 | Mar 2024 → Mar 2025 | thrombotic disease | Sirius Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06116617 | Jan → Dec 2024 | thrombotic disease | Sirius Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07140523 | Sep 2025 → Jun 2026 overdue | venous thromboembolism | Sirius Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07318155 | Mar 2025 → Dec 2027 expected | coronary artery disorder, peripheral arterial disease | Sirius Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRSD107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318155 ↗ |
| Action | Inhibit | “which reduces FXI protein.” NCT06116617 ↗ |
| Modality | Small interfering RNA (siRNA) | “small interfering ribonucleic acid (siRNA)” NCT06116617 ↗ |
| Route | Subcutaneous | “SRSD107 for subcutaneous (s.c.) injection” NCT06116617 ↗ |